Found: 5
Select item for more details and to access through your institution.
(RTH05) Characterization of the Pharmacokinetics and Pharmacodynamics of Satralizumab, a Recycling Antibody, to Support Once-Every-4-Weeks Dosing in Patients with Neuromyelitis Optica Spectrum Disorder.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 78
- By:
- Publication type:
- Article
(RTH02) Adolescents with Neuromyelitis Optica Spectrum Disorder Achieved Similar Exposures and Favorable Safety Profile When Treated with the Adult Satralizumab Dosing Regimen.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 77
- By:
- Publication type:
- Article
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA<sub>A</sub>-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.
- Published in:
- Journal of Neurodevelopmental Disorders, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s11689-022-09418-0
- By:
- Publication type:
- Article
Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-87307-7
- By:
- Publication type:
- Article
Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients B. E. Davies et al. Effect of oseltamivir in warfarinized patients.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 70, n. 6, p. 834, doi. 10.1111/j.1365-2125.2010.03780.x
- By:
- Publication type:
- Article